Blar i NTNU Open på forfatter "Hansen, Karin Holmskov"
-
Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study
Eide, Inger Johanne; Grut, Harald; Helland, Åslaug; Ekman, Simon; Sørensen, Jens Benn; Hansen, Karin Holmskov; Grønberg, Bjørn Henning; Cicenas, Saulius; Koivunen, Jussi Pekka; Mellemgaard, Anders; Brustugun, Odd Terje (Peer reviewed; Journal article, 2021)Introduction Osimertinib is effective for relapsed T790M-positive patients with brain metastases. The high brain permeability suggests that also such patients without T790M could benefit. Therefore, we evaluated the effect ... -
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials
Eide, Inger Johanne Zwicky; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Sørensen, Boe Sandahl; Brustugun, Odd Terje (Peer reviewed; Journal article, 2022)Background: Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer (NSCLC) patients. The efficacy of the drug in patients with mutations other than the common deletion in exon 19 and L858R in exon 21 ... -
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Eide, Inger Johanne; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders; Hansen, Karin Holmskov; Cicenas, Saulius; Koivunen, Jussi; Grønberg, Bjørn Henning; Brustugun, Odd Terje (Peer reviewed; Journal article, 2020)Objectives In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of ...